All Stories

  1. Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study
  2. Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study
  3. Prevalence and Predictors of Achieving Sustained Remission in Psoriatic Arthritis: A Swedish Nationwide Registry Study
  4. Predictors of treatment outcomes for Hepatitis C infection in a nationwide elimination program in Iceland: The treatment as prevention for Hepatitis C (TraP HepC) study
  5. Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia
  6. Comparing DAPSA, DAPSA28, and DAS28‐CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
  7. Deciphering the genetics and mechanisms of predisposition to multiple myeloma
  8. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
  9. Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance
  10. Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy: results from the ICEBIO registry
  11. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance
  12. Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
  13. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
  14. Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden
  15. Trends of perceived disruption in healthcare services during the pandemic: findings from the COVID-19 National Resilience Cohort in Iceland
  16. Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study
  17. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index
  18. Long COVID in Icelandic Children: A Matched Cohort Study of Nonspecific Symptoms Following SARS-CoV-2 Infection
  19. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration
  20. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study
  21. Physical and cognitive impact following SARS-CoV-2 infection in a large population-based case-control study
  22. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries
  23. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
  24. Prevalence of smoldering multiple myeloma based on nationwide screening
  25. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
  26. Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
  27. Comment on: Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen: reply
  28. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study
  29. SARS-CoV-2 Infections in Icelandic Children: Close Follow-up of All Confirmed Cases in a Nationwide Study
  30. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
  31. Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance
  32. Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen
  33. High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program—A Prospective Nationwide, Population-Based Study
  34. Symptoms, physical measures and cognitive tests after SARS-CoV-2 infection in a large population-based case-control study
  35. Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting
  36. The first wave of COVID‐19 and concurrent social restrictions were not associated with a negative impact on mental health and psychiatric well‐being
  37. A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program
  38. Does biologic therapy impact the development of PsA among patients with psoriasis?
  39. Validity of chronic disease diagnoses in Icelandic healthcare registries
  40. Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study
  41. Outpatient Use of Antimicrobials in Patients With Rheumatoid Arthritis Before and After Treatment With Tumor Necrosis Factor Inhibitors: A Nationwide Retrospective Cohort Study
  42. Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study
  43. Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis: A Set of Parallel Case-control Studies
  44. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study
  45. No One Will be Safe Until Our Children are Safe: Parent’s Attitude Towards COVID-19 Childhood Immunization
  46. Illness severity and risk of mental morbidities among patients recovering from COVID-19: a cross-sectional study in the Icelandic population
  47. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
  48. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
  49. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland
  50. Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting
  51. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study
  52. Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance
  53. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis
  54. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study
  55. FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease
  56. Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis
  57. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA
  58. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible
  59. Golimumab in the treatment of psoriatic arthritis
  60. Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct‐acting antiviral agents
  61. Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review
  62. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
  63. Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis
  64. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study
  65. Treatment as Prevention for Hepatitis C (TraP HepC). A Real-world Experience from the First 12 Months of a Nationwide Elimination Program in Iceland
  66. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries
  67. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis
  68. Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study
  69. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
  70. Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group
  71. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
  72. Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network
  73. Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis
  74. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study
  75. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study
  76. Prevalence and treatment patterns of psoriatic arthritis in the UK
  77. Psoriatic Arthritis and Onycholysis — Results from the Cross-sectional Reykjavik Psoriatic Arthritis Study
  78. Obesity and the risk of psoriatic arthritis: a population-based study
  79. Re: Risk of malignancy associated with Lyme disease: Still up in the air
  80. Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden
  81. Prevalence of the Metabolic Syndrome in Psoriasis
  82. Validation of Psoriatic Arthritis Diagnoses in Electronic Medical Records Using Natural Language Processing
  83. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis
  84. Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study
  85. A strong heritability of psoriatic arthritis over four generations--the Reykjavik Psoriatic Arthritis Study
  86. A ‘pilot’ study on air-travel and venous thromboembolism
  87. The relationship between cancer and rheumatoid arthritis: still a large research agenda
  88. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+ T cells